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Free radicalsWe previously showed that xanthine oxidase activity increases in type I diabetic animals and that this is a
significant cause of the oxidative stress which occurs in the disease. The aim of this work was to search for
molecular links between xanthine oxidase-induced oxidative stress and inflammation in Type I diabetes and
to assess the ability of allopurinol, a drug widely used in clinical practice, to prevent both processes.
3-month-old male Wistar rats were made diabetic by injection (i.p.) of either streptozotocin or alloxan.
Allopurinol (32 mg/Kg) was administered (i.p) to diabetic rats after they had shown clear signs of diabetes
such as glucosuria and polyuria.
Hepatic phospho-IKKβ and phospho-IκBα contentswere increased in diabetic animals. Thiswas accompanied by
increased levels of NF-κB (p65 protein content) in liver nuclear extracts. Hepatic expression of NF-κB dependent
inflammatory cytokines and enzymes, namely interleukin 1β, iNOS and interleukin 6 were markedly increased.
Both diabetes-induced activation of NF-κB signalling cascade and subsequent over expression of inflammatory
cytokines and enzymes were abolished by administration of allopurinol. Moreover, we found a significant
neutrophil infiltration in the liver of diabetic animals. These events were also prevented by administration of
allopurinol.ulty of Medicine, Blasco Ibañez,
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
The occurrence of oxidative stress in diabetes has been well
documented [1–4]. We previously reported that xanthine oxidase
plays an important role in the development of oxidative stress
occurring in diabetes [5]. Our results were later confirmed by other
groups [6]. On the other hand oxidative stress plays a pivotal role in
the pathophysiology of inflammation [7] which is a critical compo-
nent of the cascade of events leading to the development of diabetic
complications. In relation to this, we previously found that mice in
which hepatic NF-κB was selectively knocked out, were protected
against fat-induced insulin resistance [8]. Further, diabetes increases
the risk of chronic liver diseases like hepatic necrosis [9] or
hepatocellular carcinoma [10,11]. It has also been shown that diabetes
predisposes to non-alcoholic steatohepatitis which progresses to
cirrhosis in 5-20% of the cases [12,13].
The aim of this paper was to identify molecular links between
xanthine oxidase-derived oxidative stress and inflammation in
diabetes, and to prevent such an inflammatory state through theinhibition of xanthine oxidase activity with allopurinol, a drug widely
used in clinical practice.
Wehave found that theoxidative stress inducedbyxanthineoxidase
is responsible for the activation of the NF-κB signalling pathway. This, in
turn, up-regulates the levels of inflammatory proteins like interleukin
1β, interleukin 6 and iNOS. As a consequence of such an inflammatory
state, a significant infiltration by polymorphonuclear cells was consis-
tently observed in the liver of type I diabetic animals. Oxidative redox
imbalance, inflammatory reactions and hepatic changes were all
inhibited by treatment with allopurinol.
Materials and methods
Animals
We used 3-month-old male Wistar rats made diabetic by injection
(i.p.) of either streptozotocin or alloxan. The experimental protocol
was approved by the Committee on Ethics in Research of the Faculty
of Medicine, Valencia.
For the streptozotocin experimentswe injected i.p. thedrug (55 mg/
kg body wt dissolved in 0.8 ml of 0.1 mol/l citrate buffer, pH 4.5). The
rats had polyuria, polydipsia, and weight loss 7-10 days after the drug
administration.
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dissolved in saline). The rats had polyuria, polydipsia, and weight loss
9-11 days after the drug administration.
All animals with a glucosuria of N20 g/l were considered diabetic.
Control animals were injected with the same volume of citrate
buffer or saline as the diabetic animals but without streptozotocin or
alloxan.
Allopurinol administration
Allopurinol (32 mg/Kg) was administered intraperitoneally to rats
5 days after theyhad shownclear signsof diabetes suchus glucosuria and
polyuria. Doses were given 30 h and 6 h before the rats were sacrificed
[5].
0.35 mL of DMSO was used as a vehicle for the allopurinol
experiments. Diabetic animals were injected with the same volume of
DMSO as those diabetic treated with allopurinol. Only animals made
diabetic with streptozotocin were treated with allopurinol.
All the animalswere killed by an overdose of sodiumpentobarbitone.
Determination of reduced glutathione (GSH), oxidized glutathione (GSSG)
and of Malodialdehyde (MDA)
GSH and GSSG were determined in liver from rats by HLPC
following the protocol described in [14] andMDA as described in [15].
Determination of XO activity
XO activity was determined in rat liver and plasma by a
fluorimetric method [16]. Frozen liver was homogenized with 5
volumes per gram of tissue of 0.25 M sucrose, 10 mM DTT, 0.2 mM
PMSF, 0.1 mM EDTA and 50 mM K-phosphate, pH 7.4. Homogenates
were centrifuged for 30 minutes at 15,000×g and activities measured
in supernatants. XO activity was measured by calculating the slope of
the increase in fluorescence after adding pterin (0.010 mmol/L),
which actually measures conversion of pterin to isoxanthopterin. The
reaction was stopped by adding allopurinol (50 µmol/L). To calibrate
the fluorescence signal, the activity of a standard concentration of
isoxanthopterin was measured. Values are expressed as nmol/min
per gram of protein. Protein concentration of homogenates was
determined by the Bradford assay [17].
Nuclear extract preparation
Nuclear extracts were obtained following themethod of Dignam et
al. [18], with slight modifications [19], and protein content was
determined by the Bradford method [17].
Western blot analysis
Aliquots of liver lysate (20–40 μg) were separated by SDS-PAGE
electrophoresis. Proteins were then transferred to nitrocellulose
membranes, which were incubated overnight at 4 °C with appropriate
primary antibodies. Antibodies against iNOS, phospho-IKKβ, phospho-
IκB, P65 and α-tubulin were purchased from Cell Signaling Technology
Inc (Beverly,MA, USA). Thereafter, membranes were incubated with a
secondary antibody for 1 h at room temperature. Oxidativemodification
of total proteins was assessed by immunoblot detection of protein
carbonyl groups using the ‘OxyBlot’ protein oxidation kit from Intergen
Company (Purchase, NY) following the manufacturer's instructions.
Approximately 20 μg of total protein was loaded onto paired gels and
electrophoretically separated. Immunoblots of one gel from each pair
were prepared, with the other gel stained in Coomassie blue and used
for verification of equality of lane loading [20,21]. Antibody anti-
dinitrophenylhydrazone was purchased from Intergen Company (Pur-
chase, NY). The procedure to quantify total protein carbonyls with theOxyBlot kitwasdensitometry of the oxyblot andof thePonceau staining,
followed by finding the ratio between the total density in the oxyblot
and the total density in the Ponceau [22]. Specific proteins were
visualised by using the enhanced chemiluminescence (ECL) procedure
as specifiedby themanufacturer (Amersham). Autoradiographic signals
were assessed using a BioRad scanning densitometer.
Interleukins
The concentrations of IL-6 and IL-1β in rat liver was determined by
ELISA (Amersham-Biosciences). For each individual cytokine the
manufacturer's protocol was followed.
Number of neutrophils
Fragments of liver of an approximate size 1.0×0.5×0.3 cm were
placed overnight in a solution of 4% formaldehyde in 50 mMphosphate
buffer solution, pH 7.4. Polymorphonuclear leukocytes (PMN) were
identified on 5-mm paraffin sections by means of the naphthol AS-D
chloroacetate technique for esterase, following themethoddescribed by
Moloney et al. (1960) [23] with slight modifications; the substrate was
dissolved in dimethyl sulphoxide/Triton X-100 (9:1, v/v) and then 0.1%
Fast Garnet dGBC in 0.1 M phosphate buffer solution, pH 8.5 was added.
Red stained PMN were counted in 20 non-consecutive, randomly
chosen x 500 histological fields. Results were expressed as the number
of neutrophils per 40 x histological power field (hpf).
Statistics
Results are presented as mean±standard deviation indicating the
number of observations (n) in brackets. The statistical treatment of
the results when comparing control, diabetic and diabetic treated
with allopurinol groups, was carried out after finding normal data
distribution with Shapiro-Wilk test. As several groups of data did not
show normal distribution, the means of the groups were compared
with a non-parametric test, Kruskal-Wallis. The null hypothesis
considered the lack of differences between the group means and
was rejected for P valuesb0.05. Post-hoc comparisons were then
performed with the Mann-Witney U test. In some cases in which just
2 groups were compared, we used an Student t test. In all
comparisons, the null hypothesis was rejected with P valuesb0.05.
Statistical treatment of the results was carried out with SPSS software
version 11.01, for Windows.
Results
Increase in xanthine oxidase activity in experimental diabetes
We first of all studied whether xanthine oxidase is activated in
experimental diabetes. We used two well established experimental
models of insulin-dependent diabetes: streptozotocin or alloxan. In
both models diabetic rats showed a significant increase of plasma and
hepatic xanthine oxidase activity, which was abolished when diabetic
animals were treated with allopurinol (See Figs. 1 and 2).
Allopurinol prevents oxidative stress associated with diabetes
As shown in Fig. 3, treatment with allopurinol diminished the
oxidative stress associated with diabetes.
Plasma malondialdehyde (MDA) levels of diabetic rats were more
than threefold higher than those of corresponding controls. This was
almost completely abolished by treatment with allopurinol (panel A).
Whole blood of diabetic rats showed a glutathione redox ratio (GSSG/
GSH) which was approximately 50% higher than that of controls. This
was completely prevented by treatment with allopurinol (panel B).
Carbonylated proteins in cytosolic extracts from liver were fivefold
Fig. 1. Allopurinol prevents the activation of xanthine oxidase in streptozotocin-
induced diabetes. (A) Plasma XO activity increases in streptozotocin-induced diabetes
in rats. Allopurinol administration prevents this effect. Values are mean±SD. Control
group, N=5; Diabetic group, N=4; Diabetic treated with allopurinol, N=5. (**)
indicates pb0.01 vs control. ($$) indicates pb0.01 vs diabetes. Group means were
compared using the Kruskal-Wallis test. Post-hoc comparisons were performed using
the Mann-Witney U test. (B) Liver XO activity increases in streptozotocin-induced
diabetes in rats. Allopurinol administration prevents this effect. Values are mean±SD.
Control group, N=3; Diabetic group, N=4; Diabetic treated with allopurinol, N=4. (*)
indicates pb0.05 vs control. (**) indicates pb0.01 vs control. ($$) indicates pb0.01 vs
diabetes. Group means were compared using the Kruskal-Wallis test. Post-hoc
comparisons were performed using the Mann-Witney U test.
Fig. 2. Activation of xanthine oxidase in alloxan-induced diabetes. (A) Plasma XO
activity increases in an alloxan-induced diabetes in rats. Values are mean±SD. Control
group, N=3; Diabetic group, N=3. (*) indicates pb0.05 vs control. Group means were
compared using the Student t test. (B) Liver XO activity increases in an alloxan-induced
diabetes in rats. Values are mean±SD. Control group, N=6; Diabetic group, N=6. (*)
indicates pb0.05 vs control. Group means were compared using the Student t test.
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allopurinol significantly prevented the liver protein oxidation in the
diabetic animals.
Allopurinol prevents diabetes-associated activation of the NF-κB
signalling pathway
NF-κB activation is highly dependent on oxidative stress. On the
basis of the results reported in Fig. 3 the activation of NF-κB signalling
pathway was evaluated in diabetic animals and its possible preven-
tion by allopurinol checked. As reported in Fig. 4A the level of
phosphorylated IKKβ was approximately threefold higher in diabetic
animals than in the corresponding controls. Such activation was fully
inhibited by treatment with allopurinol, thus pointing to the
involvement of xanthine oxidase in the up-regulation of the NF-κB
pathway observed in diabetes. Downstream of IKKβ activation is the
activation of IκBα, Fig. 4B also shows that the hepatic level of
phosphorylated IκBα, i.e. the inhibitory protein which binds to NF-κB
preventing its translocation into the nucleus, was increased in
diabetes but significantly down-regulated by allopurinol. The next
event in the activation of NF-κB pathway is its translocation to the
nucleus, easily checked by measuring the increased level of p65 unitin nuclear extracts. We found that p65 (See Fig. 4C) in nuclear hepatic
extracts from diabetic animals was higher that in controls and that
this was inhibited by allopurinol.
Allopurinol prevents the diabetes-associated up-regulation of interleukin 6,
interleukin 1β and iNOS
NF-κB is involved in the regulation of hundreds of genes, several of
them involved in inflammation. Prominent among these genes are
those coding for key inflammatory cytokines, like interleukin 6 (IL-6)
and interleukin 1β (IL-1β) and for the inducible nitric oxide synthase.
Table 1 and the supplementary material show that the hepatic levels
of these proteins were markedly elevated in diabetic animals but
significantly quenched in case of allopurinol administration.
Neutrophil infiltration in the liver of diabetic animals
Prevention by allopurinol administration
After studying the molecular mechanisms linking xanthine oxidase
activation in diabetes to the inflammatory response mediated by free
radicals and the NF-κB signalling pathway, we turned to histology to
determine the cellular effects of diabetes in liver andwhether this could
be prevented by treatment with allopurinol. We measured the
neutrophil infiltration in liver of diabetic animals. Fig. 5 shows that
the number of polymorphonuclear cells was more than fourfold in
streptozotocin-injected animals than in controls, and partially but
significantly reduced by allopurinol. Neutrophil infiltration is a clear
Fig. 3. Allopurinol prevents oxidative stress in streptozotocin-induced diabetes. (A) Liver MDA levels increase in streptozotocin-induced diabetes in rats. Administration of allopurinol
prevents this effect. Values are mean±SD. Control group, N=4; Diabetic group, N=5; Diabetic treated with allopurinol, N=4. (*) indicates pb0.05 vs control. ($)indicates pb0.05 vs
diabetes. (B) Allopurinol prevents oxidation of liver glutathione in streptozotocin-induced diabetes in rats. (GSSG/GSH)*100 levels in liver. Values are mean±SD. Control group, N=4;
Diabetic group,N=6;Diabetic treatedwith allopurinol,N=4. (*) indicates pb0.05vs control.($) indicates pb0.05vsdiabetes. (C)Allopurinol prevents liver protein oxidation in ratsmade
diabeticwith streptozotocin.Westernblottinganddensitometryanalysis (MW:29kD) showingcarbonylatedproteins in cytosolic extracts from liver.Valuesaremean±SD.Control group,
N=3; Diabetic group, N=3; Diabetic treated with allopurinol, N=3. (**) indicates pb0.01 vs control.($$)indicates pb0.01 vs diabetes. Group means were compared using the Kruskal-
Wallis test. Post-hoc comparisons were performed using the Mann-Witney U test.
Fig. 4. Allopurinol prevents the phosphorylation of IKKβ, IκBα and the traslocation to the nucleus of NF-κB (p65) in liver of rats made diabetic with streptozotocin. Densitometry
analysis of cytosolic p-IKKβ, p-IκBα, nuclear p65 subunit and α-tubulin in liver of diabetic rats. Values are mean±SD. Control group, N=3; Diabetic group, N=3; Diabetic treated
with allopurinol, N=3. (*) indicates pb0.05 vs control. ($) indicates pb0.05 vs diabetes.(**) indicates pb0.01 vs control. Representative experiments are shown. The content of
α-tubulin, a house-keeping protein marker in liver, was not altered in the various treatment groups of rats. Group means were compared with the Kruskal-Wallis test. Post-hoc
comparisons were performed using the Mann-Witney U test.
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Table 1
Inteleukin levels in liver of diabetic animals. Effect of allopurinol administration. Values
are mean±SD. Control group, N=4; Diabetic group, N=4; Diabetic treated with
allopurinol, N=4. (*) indicates pb0.05 vs control.($)indicates pb0.05 vs diabetes
LIVER IL-6 IL-1β
(μg/g of tissue) (μg/g of tissue)
Control (4) 47,1±5,3 20,7±5,9
Diabetes (4) 72,6±13,7* 35,3±5,2*
Diabetes + Allopurinol (4) 53,0±06,4$ 25,2±4,9$
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cells.Fig. 5. Neutrophil infiltration in liver of rats made diabetic with streptozotocin. Effect of
allopurinol administration. (A) A representative image showing PMN infiltration is
shown for every experimental group. PS: Portal Space. (B) Values are mean±SD.
Control group, N=4; Diabetic group, N=4; Diabetic treated with allopurinol, N=5.
(**) indicates pb0.01 vs control. ($)indicates pb0.05 vs diabetes. Group means were
compared using the Kruskal-Wallis test. Post-hoc comparisons were performed using
the Mann-Witney U test.Discussion
The occurrence of oxidative stress in diabetes has been well
documented. Work from several laboratories, including our own [5]
has shown that diabetes, both clinical and experimental, causes
oxidative stress as measured by an increased level of hydroperoxides,
an oxidation of glutathione, an increase in levels of oxidised proteins
and other signs of oxidation to cell components. This is of particular
importance in the development of the very serious late onset
complications of diabetes [24], like atherosclerosis [25], retinopathy
[26], and nephropathy [27]. However, the hepatic complications of
diabetes have been somewhat neglected. In fact, diabetes causes an
increased risk of chronic liver diseases [10] and even of acute hepatic
necrosis and failure [9].
For the majority of experiments in this paper we have used
streptozotocin to induce diabetes. However, to show that the effects
on oxidative stress caused by experimental diabetes were not due to
streptozotocin itself, but rather to the lack of insulin caused by this
toxic drug, we used another one, i.e. alloxan. When we treated rats
with alloxanwe found that xanthine oxidase activity, both in liver and
in blood, was increased (see Figs. 2A and B). Thus, the effects that we
find are not due to streptozotocin but rather to the diabetic state
caused by either streptozotocin or alloxan.
Diabetes has been considered as an inflammatory disease [28]. Our
guiding hypothesis was that inflammation could be important in the
development of hepatic complications in diabetes [29]. This in turn,
might result in changes in glucose homeostasis whichmay complicate
the prognosis of the disease.
Several pathogenetic mechanisms have been proposed to explain
the oxidative state which occurs in diabetes. Hyperglycaemia itself is
one of suchmechanisms, albeit not the only one [30]. For instance Jain
and co-workers suggested that the ketone bodies which are increased
in all forms of diabetes, but particularly in type I, cause oxidative stress
in many cases by auto oxidation [31]. Advanced glycosylation end
products also play a major role in the cellular toxic effects associated
with diabetes [32]. Some classical enzymatic mechanisms have been
proposed as causes of oxidation in diabetes. Prominent among these is
NADPH oxidase [33] (whose activity is increased in diabetes). Its
localisation near or at the vascular bed makes it a critically important
enzyme in the local oxidation leading to atherosclerosis [34,35].
Work from our laboratory showed that xanthine oxidase, another
oxidase which is active and causes oxidative stress in several
pathological states such as the ischemia reperfusion syndrome, is an
important determinant of the oxidation that we observe in diabetes.
An important point related to this enzyme is that we can inhibit it by
using a well known, quite safe drug, namely allopurinol which has
been used for decades to treat hyperuricemia. Although it has been
suggested that allopurinol generates superoxide radical in liver [36]
we have previously shown that allopurinol prevents, to a large extent,
oxidative stress which occurs in diabetes [5] and in other pathophys-
iological situations like exhaustive exercise [37]. Other groupsconfirmed our findings pointing to the important role of xanthine
oxidase in the pathophysiology of the disease [6].
We tested the role of allopurinol in the prevention of diabetic
complications and in particular of those associated with the liver. We
chose the liver because, as we proved earlier it is the main source of
xanthine oxidase which is shed by it and released to the blood plasma
and then distributed along all the vascular bed where it is anchored to
the endothelium by a heparan sulphate [5]. But amajor site of damage
caused by this enzyme is very likely to be at the site of production,
namely the liver. In this organ we have studied the role of xanthine
oxidase-derived reactive oxygen species in the activation of the
cascade of molecular events leading to oxidation, and eventually to
liver inflammation. NF-κB is one of the major transcription factors
involved in unleashing the cascade of events leading to inflammation
[38]. Different research groups have demonstrated its activation in the
diabetic liver [29,39,40].
The data we present in the Results section show that the oxidative
stress condition induced by xanthine oxidase activation in the liver of
streptozotocin-treated rats leads to a marked up-regulation of the
NF-κB pathway. The latter was evaluated in terms of IKKβ and IκBα
increased phosphorylation, and definitely supported by the significant
rise of IL-6, IL-1β and iNOS protein levels observed in the hepatic
tissue of the same animals. As for the two cytokines'genes also iNOS
gene has mandatory NF-κB binding sequences on their promoter
region [41]. Notably, even if secondary modifiers such as oxidants and
NO itself could in principle alter NF-κB binding despite nuclear
translocation, the net increase of the two inflammatory cytokines and
of the enzyme demonstrates the actual induction of a NF-κB
dependent inflammatory state in the diabetic rats. In addition, it has
been demonstrated that iNOS plays a major role in the induction of
albuminuria in diabetes and is of critical importance in the onset of
inflammation as well [42].
The observed activation of liver NF-κB and consequent molecular
events were bound to have histological repercussions. Fig. 5 shows
176 M. Romagnoli et al. / Free Radical Biology & Medicine 49 (2010) 171–177polimorphonuclear infiltration in the liver of diabetic animals which is
prevented by allopurinol.
We consider that the main importance of the finding reported in
our manuscript lies in the fact that a widely used drug in the clinical
practise, allopurinol, can be used to decrease NF-κB activation and
inflammation associated with diabetes. We do not consider that,
although the effects of oxypurinol (a metabolite which is not used in
clinical practice), could reproduce or even improve the results found
in our study, it could reach the clinical significance that we have
obtained with allopurinol.
Inhibition of xanthine oxidase prevents signs of oxidative stress
which occur in diabetes, thus confirming our previous work where we
showed the relevance of this enzyme in the process of oxidation
associated with diabetes.
The fact that inhibition of xanthine oxidase protects against
oxidative stress associated with a number of physiological and
pathological processes is well documented. For instance, we showed
that allopurinol prevents oxidative stress and cell damage which
occurs in strenuous physical exercise such as that of the Tour de
France [37]. In 2001 Jain and co-workers showed that XO-derived free
radicals contribute to liver necrosis and that it was prevented by the
administration of allopurinol [43]. In a similar fashion allopurinol
prevented early alcohol-induced liver injury [44] and a number of
complications associated with the ischaemia reperfusion syndrome
[45]. It has also recently been shown that treatment with allopurinol
improves nerve and vascular function in diabetic rats [46] which
points out that inhibition of xanthine oxidase could be a potential
therapeutic approach to diabetic neuropathy and vasculopathy
[46,47].
Work reported here shows that allopurinol prevents the cascade of
cell signals which lead to inflammatory signs associatedwith diabetes.
The possible role of allopurinol to treat late onset complications of
diabetes which are sparkled by inflammation should be studied in the
clinical setting.
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